To uncover the ontogenesis of the human indusium griseum (IG), 28 post-mortem fetal human brains, 12-40 postconceptional weeks (PCW) of age, and 4 adult brains were analyzed immunohistochemically and compared with post-mortem magnetic resonance imaging (MRI) of 28 fetal brains (14-41 PCW). The morphogenesis of the IG occurred between 12 and 15 PCW, transforming the bilateral IG primordia into a ribbon-like cortical lamina. The histogenetic transition of sub-laminated zones into the three-layered cortical organization occurred between 15 and 35 PCW, concomitantly with rapid cell differentiation that occurred from 18 to 28 PCW and the elaboration of neuronal connectivity during the entire second half of gestation. The increasing number of total cells and neurons in the IG at 25 and 35 PCW confirmed its continued differentiation throughout this period. High-field 3.0 T post-mortem MRI enabled visualization of the IG at the mid-fetal stage using T2-weighted sequences. In conclusion, the IG had a distinct histogenetic differentiation pattern than that of the neighboring intralimbic areas of the same ontogenetic origin, and did not show any signs of regression during the fetal period or postnatally, implying a functional role of the IG in the adult brain, which is yet to be disclosed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/cercor/bhz004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS-FTD.
Nat Med
February 2024
Department of Pathology, Johns Hopkins Medicine, Baltimore, MD, USA.
Although loss of TAR DNA-binding protein 43 kDa (TDP-43) splicing repression is well documented in postmortem tissues of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), whether this abnormality occurs during early-stage disease remains unresolved. Cryptic exon inclusion reflects loss of function of TDP-43, and thus detection of proteins containing cryptic exon-encoded neoepitopes in cerebrospinal fluid (CSF) or blood could reveal the earliest stages of TDP-43 dysregulation in patients. Here we use a newly characterized monoclonal antibody specific to a TDP-43-dependent cryptic epitope (encoded by the cryptic exon found in HDGFL2) to show that loss of TDP-43 splicing repression occurs in ALS-FTD, including in presymptomatic C9orf72 mutation carriers.
View Article and Find Full Text PDFMultimodal, broadly neutralizing antibodies against SARS-CoV-2 identified by high-throughput native pairing of BCRs from bulk B cells.
Cell Chem Biol
November 2023
Adaptive Biotechnologies, Seattle, WA 98109, USA. Electronic address:
TruAB Discovery is an approach that integrates cellular immunology, high-throughput immunosequencing, bioinformatics, and computational biology in order to discover naturally occurring human antibodies for prophylactic or therapeutic use. We adapted our previously described pairSEQ technology to pair B cell receptor heavy and light chains of SARS-CoV-2 spike protein-binding antibodies derived from enriched antigen-specific memory B cells and bulk antibody-secreting cells. We identified approximately 60,000 productive, in-frame, paired antibody sequences, from which 2,093 antibodies were selected for functional evaluation based on abundance, isotype and patterns of somatic hypermutation.
View Article and Find Full Text PDFA single ascending dose study of single-stranded oligodeoxyribonucleotide RO7062931 in Chinese healthy volunteers.
Clin Transl Sci
July 2023
Roche Innovation Center, New York, New York, USA.
RO7062931 is an N-acetylgalactosamine (GalNAc)-conjugated single-stranded oligodeoxyribonucleotide complementary to hepatitis B virus RNA. GalNAc conjugation targets the liver through the asialoglycoprotein receptor (ASGPR). This phase I single ascending dose (SAD) study evaluated the safety, tolerability, and pharmacokinetics of RO7062931 in Chinese healthy volunteers.
View Article and Find Full Text PDFPositive Impact of the Bionic Pancreas on Diabetes Control in Youth 6-17 Years Old with Type 1 Diabetes: A Multicenter Randomized Trial.
Diabetes Technol Ther
October 2022
JAEB Center for Health Research, Tampa, Florida, USA.
To evaluate the insulin-only configuration of the iLet bionic pancreas (BP) in youth 6-17 years old with type 1 diabetes (T1D). In this multicenter, randomized, controlled trial, 165 youth with T1D (6-17 years old; baseline HbA1c 5.8%-12.
View Article and Find Full Text PDFMulticenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes.
N Engl J Med
September 2022
The authors' affiliations are as follows: the Diabetes Research Center, Massachusetts General Hospital (S.J.R., C.A.B., J.S.S., L.E.C., M.A.H., M.T., M.S.P., M.Y.S.), and Boston University (E.R.D.), Boston, and Beta Bionics, Concord (E.R.D., F.H.E.-K.) - all in Massachusetts; the Jaeb Center for Health Research, Tampa (R.W.B., K.J.R., Z.L., P.C.), and Nemours Children's Health Jacksonville, Jacksonville (N.M., M. Benson, K. Bird, K.E., J. Permuy) - both in Florida; the Barbara Davis Center for Diabetes, University of Colorado, Aurora (R.P.W., G.F., R.S., L.H.M., E.C., V.N.S., S.P.); Stanford University School of Medicine, Palo Alto (B.B., R.L., L.E., M.S.H., M. Basina), Children's Hospital of Orange County, Orange (M.D., A. Bhangoo, N.F., H.K., F.S.), and the University of California, San Diego, La Jolla (J. Pettus, S.B.) - all in California; Cleveland Clinic, Cleveland (K.Z., B.H., L.O.); University of Texas Southwestern Medical Center, Dallas (P.R., P.C.W., A. Choudhary, J. Penn), and University of Texas Health Science Center, San Antonio (J.L., R.J., M.R., E.E., C.K., R.F.-P.); the University of Washington, Seattle (I.B.H., S.T.); the Naomi Berrie Diabetes Center, Columbia University, New York (R.G., K.M.W., N.L.); the University of North Carolina, Chapel Hill (J.B.B., M.S.K., K. Bergamo, K.R.K., J.M.D., S. Machineni, L.A.Y., J.C.D.); the Henry Ford Health System, Detroit (D.K., A. Bhan, J.K.J.); Emory University, Atlanta (A.M., K.C., E.F.); Washington University in St. Louis, St. Louis (J.B.M., M.S., J.M.S., S.A., A. Cedeno); Children's National Hospital, Washington, DC (F.C., S. Meighan, A.D.); and the Pritzker Department of Psychiatry and Behavioral Health, Ann and Robert Lurie Children's Hospital, Chicago (J.W.-B.).
Background: Currently available semiautomated insulin-delivery systems require individualized insulin regimens for the initialization of therapy and meal doses based on carbohydrate counting for routine operation. In contrast, the bionic pancreas is initialized only on the basis of body weight, makes all dose decisions and delivers insulin autonomously, and uses meal announcements without carbohydrate counting.
Methods: In this 13-week, multicenter, randomized trial, we randomly assigned in a 2:1 ratio persons at least 6 years of age with type 1 diabetes either to receive bionic pancreas treatment with insulin aspart or insulin lispro or to receive standard care (defined as any insulin-delivery method with unblinded, real-time continuous glucose monitoring).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!